America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What types of cancers have shown positive responses to AOH1996 in research studies?
**Interview with Dr. Linda Malkas on AOH1996: A Revolutionary Cancer Treatment**
**Editor**: Today, we have Dr. Linda Malkas, a prominent researcher from City of Hope Hospital, known for her groundbreaking work in cancer treatment. Dr. Malkas, could you tell us about your recent development, AOH1996, and how it aims to treat cancer?
**Dr. Malkas**: Absolutely! AOH1996 is a novel drug designed to target cancer cells specifically by disrupting a key protein involved in DNA replication called PCNA. By focusing on this variant of PCNA, we can selectively kill cancer cells without harming normal ones. It’s akin to creating a blizzard that halts all flights in a busy airport, but only those carrying cancer cells.
**Editor**: Fascinating analogy! What types of cancer have shown promising results from your research?
**Dr. Malkas**: Our research has indicated that AOH1996 is effective against several aggressive cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. We have tested this molecule on over 70 cancer cell lines, and the results were incredibly encouraging.
**Editor**: Could you elaborate on how this drug works in a clinical setting?
**Dr. Malkas**: Certainly. In our studies published in ‘Cell Chemical Biology,’ we found that AOH1996 selectively interferes with the reproductive cycle of cancer cells, leading to cell death. The next step is to conduct human clinical trials to evaluate its safety and effectiveness in patients.
**Editor**: What do you see as the potential impact of AOH1996 on cancer treatment?
**Dr. Malkas**: If successful in clinical trials, AOH1996 could represent a significant advancement in targeted chemotherapy, potentially offering a more effective and less toxic option for cancer treatment. It’s a promising step toward personalized medicine, tailoring treatments to the unique characteristics of a patient’s tumor.
**Editor**: Thank you, Dr. Malkas, for sharing these insights into your important work on AOH1996. We look forward to seeing how it progresses in clinical trials.
**Dr. Malkas**: Thank you for having me. We’re excited about the future of cancer treatment!
